Skip to main content
. Author manuscript; available in PMC: 2012 Jan 17.
Published in final edited form as: Vaccine. 2010 Nov 21;29(4):772–777. doi: 10.1016/j.vaccine.2010.11.013

Figure 3. IL-17 contributes to LecA/alum-mediated protection.

Figure 3

Mice immunized with LecA (closed bars) or PBS (open bars) in the alum regimen were administered anti-IL-17 or control IgG from 1 day prior to 4 days after challenge (3 doses total). Mice were sacrificed seven days post-infection. *p <0.05.